Tag: thyroid cancer diagnostics market research

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Growth Rate is Predicted for the Thyroid Cancer Diagnostics Market for 2024-2033?

In recent times, the market size for thyroid cancer diagnostics has witnessed robust growth. It is anticipated to expand from $2.79 billion in 2023 to $2.97 billion in 2024 with a compound annual growth rate (CAGR) of 6.2%. Numerous factors contributed to this growth in the past such as increasing instances of thyroid cancer, ageing population, heightened awareness and early detection, governmental aid and initiatives, and enhanced healthcare infrastructure.

In the coming years, the thyroid cancer diagnostics market is projected to experience substantial growth, escalating to $3.7 billion in 2028 with a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth during the forecast period include increasing demand for companion diagnostic procedures, a rising trend towards personalized medicine among patients, economic development and healthcare expenditure, education and training of physicians, and regulatory approvals and clearances. Key trends expected in this period encompass liquid biopsies, adoption of diagnostic technologies globally, technological progress, research and development initiatives, incorporation of artificial intelligence, and collaboration and partnership strategies.

Claim Your Free Sample of the Global Thyroid Cancer Diagnostics Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12030&type=smp

What Drivers Are Enhancing the thyroid cancer diagnostics Market’s Growth?

The growth of the thyroid cancer diagnostic market is being propelled by the rising incidence of thyroid cancer. Thyroid cancer is a condition that affects the thyroid gland, a gland responsible for producing hormones that regulate body temperature, heart rate, blood pressure, and weight. Diagnostic tools for thyroid cancer facilitate early detection of the disease, improving treatment outcomes. Consequently, the growing incidence of thyroid cancer drives the demand for the diagnostic market. For example, in September 2023, a report from the American Cancer Society, a US-based non-profit organization, predicts about 43,720 new instances of thyroid cancer, with 12,540 in men and 31,180 in women. The forecasted number of thyroid cancer-related deaths in the same year stands at around 2,120, comprising 970 men and 1,150 women. Hence, the escalating incidence of thyroid cancer fuels the thyroid cancer diagnostic market’s growth.

What Segments Are Central to the Thyroid Cancer Diagnostics Market?

1) By Technique Type: Imaging Test, Blood Test, Biopsy, Other Test Type

2) By Disease Type: Papillary Carcinoma, Follicular Carcinoma, Other Diseases

3) By End-User: Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Other End-Users

What Emerging Trends Are Influencing Thyroid Cancer Diagnostics Industry Dynamics?

Key players in the thyroid cancer diagnostic market are focusing on creating groundbreaking products like oral tablets, to engage a wider customer demographic, boost sales and elevate revenue. Oral tablets are a form of solid medicament designated for oral intake. For example, in September 2021, Exelixis Inc., an American biotech firm, publicized the authorization of CABOMETYX (cabozantinib) by the U.S. Food and Drug Administration (FDA). This solution is reserved for treating differentiated thyroid cancer (DTC) in adults and children aged 12 and over who suffer from locally advanced or metastatic illness. This approach is meant exclusively for cases that have progressed post prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and patients who are either resistant to radioactive iodine or disqualified from such therapy. CABOMETYX tablets have been awarded approval for numerous applications, including the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma in patients who received prior treatment with sorafenib, first-line therapy for advanced RCC in alliance with nivolumab, and the control of locally advanced or metastatic differentiated thyroid cancer (DTC) in adult and pediatric patients aged 12 and up.

Order Now for Fast Delivery of Your Thyroid Cancer Diagnostics Market Report!

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Which Geographic Locations Are Critical to the Growth of the Thyroid Cancer Diagnostics Market?

North America was the largest region in the thyroid cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Thyroid Cancer Diagnostics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the thyroid cancer diagnostics market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Thyroid Cancer Diagnostics Market Include

1. Thyroid Cancer Diagnostics Market Executive Summary

2. Thyroid Cancer Diagnostics Market Segments

3. Thyroid Cancer Diagnostics Market Size And Template Market Growth Rate

4. Key Thyroid Cancer Diagnostics Market Trends

5. Major Thyroid Cancer Diagnostics Market Drivers

……

25. Key Mergers And Acquisitions In The Thyroid Cancer Diagnostics Market

26. Top Thyroid Cancer Diagnostics Companies

27. Thyroid Cancer Diagnostics Market Opportunities And Strategies

28. Thyroid Cancer Diagnostics Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Cancer biologics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Breast Cancer Monoclonal Antibodies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodie-global-market-report

Colorectal Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Thyroid Cancer Diagnostics Global Market Report 2024, the thyroid cancer diagnostics market is expected to show promising growth in the forecast period.

In recent years, the thyroid cancer diagnostics market has exhibited robust growth, with its size escalating from $2.79 billion in 2023 to $2.97 billion in 2024, boasting a compound annual growth rate (CAGR) of 6.2%. This growth can be attributed to various factors, including:

• Increasing prevalence of thyroid cancer
• Aging population
• Rising awareness and early detection
• Government initiatives and funding
• Improved healthcare infrastructure

Anticipated Expansion

Looking ahead, the market is poised for continued growth, with projections indicating a rise to $3.7 billion by 2028, representing a CAGR of 5.7%. Factors contributing to this anticipated growth include:

• Growing demand for companion diagnostics
• Patient preference for personalized medicine
• Economic growth and healthcare spending
• Physician education and training
• Regulatory approvals and clearances

View More On The Thyroid Cancer Diagnostics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Key Trends in the Forecast Period

Several trends are expected to shape the thyroid cancer diagnostics market in the forecast period, including:

• Adoption of liquid biopsies
• Globalization of diagnostic technologies
• Technological advancements
• Research and development initiatives
• Integration of artificial intelligence
• Collaborations and partnerships

The Surge In Thyroid Cancer Prevalence And Its Implications On The Diagnostic Market

The increasing prevalence of thyroid cancer serves as a driving force behind the expansion of the thyroid cancer diagnostics market. Thyroid cancer, affecting the thyroid gland, necessitates early detection for improved treatment outcomes. For example:

• In 2023, approximately 43,720 new cases of thyroid cancer were anticipated in the US alone.
• The growing prevalence underscores the significance of diagnostic tools in combating the disease.

Key Players in the Market

Major companies driving innovations in the thyroid cancer diagnostics market include:

• Pfizer Inc.
• General Electric
• Hoffmann-La Roche AG
• Bayer AG
• Novartis International AG

Product Innovations In The Thyroid Cancer Diagnostic Market

Companies are focusing on product innovations to cater to a larger customer base and enhance revenue streams. Notable developments include:

• FDA approval for CABOMETYX (cabozantinib) by Exelixis Inc. for treating differentiated thyroid cancer.
• Acquisition of HalioDx by Veracyte Inc., bolstering its position in cancer diagnostics.

Market Segmentation

The thyroid cancer diagnostics market can be segmented based on:

1. Technique Type: Imaging Test, Blood Test, Biopsy, Other Test Types
2. Disease Type: Papillary Carcinoma, Follicular Carcinoma, Other Diseases
3. End-User: Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others

Regional Dynamics

North America emerged as the largest region in the thyroid cancer diagnostics market in 2023. Meanwhile, Asia-Pacific is anticipated to witness the fastest growth in the forecast period, indicative of significant opportunities within the region.

In conclusion, the thyroid cancer diagnostics market presents a promising landscape, driven by factors such as increasing disease prevalence, technological advancements, and strategic collaborations. With a focus on innovation and expansion, the market is poised to address the evolving healthcare needs associated with thyroid cancer effectively.

Request A Sample Of The Global Thyroid Cancer Diagnostics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=12030&type=smp